Cargando…

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

Two phase 3 clinical studies were conducted in the USA to bridge across different Ad26.ZEBOV manufacturing processes and sites, and to evaluate the immunogenicity of different dose levels of Ad26.ZEBOV and MVA-BN-Filo. Study 1 evaluated the immunological equivalence of three batches of Ad26.ZEBOV ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bockstal, Viki, Gaddah, Auguste, Goldstein, Neil, Shukarev, Georgi, Bart, Stephan, Luhn, Kerstin, Robinson, Cynthia, Anumendem, Dickson, Leyssen, Maarten, Douoguih, Macaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688528/ https://www.ncbi.nlm.nih.gov/pubmed/34930928 http://dx.doi.org/10.1038/s41541-021-00402-8

Ejemplares similares

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
por: Mutua, Gaudensia, et al.
Publicado: (2019)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
por: Anywaine, Zacchaeus, et al.
Publicado: (2019)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Alexandre, Marie, et al.
Publicado: (2023)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Barry, Houreratou, et al.
Publicado: (2021)

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
por: Afolabi, Muhammed O, et al.
Publicado: (2022)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
por: Bockstal, Viki, et al.
Publicado: (2022)

1049. Minimal Transient HIV-1 Viremia Following Vaccination Regimens Containing AD26. ZEBOV and MVA-BN-Filo in ART-Suppressed People Living with HIV
por: Custer, Benjamin L, et al.
Publicado: (2021)

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
por: Ishola, David, et al.
Publicado: (2022)

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
por: Goldstein, Neil, et al.
Publicado: (2020)

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2020)

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
por: Manno, Daniela, et al.
Publicado: (2023)

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial
por: Karita, Etienne, et al.
Publicado: (2022)

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children( )
por: Ishola, D
Publicado: (2022)

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
por: Nyombayire, Julien, et al.
Publicado: (2022)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
por: Wagstaffe, Helen R., et al.
Publicado: (2020)

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
por: Wagstaffe, Helen R, et al.
Publicado: (2019)

Durable natural killer cell responses after heterologous two-dose Ebola vaccination
por: Wagstaffe, Helen R., et al.
Publicado: (2021)

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
por: Wagstaffe, Helen R., et al.
Publicado: (2022)

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
por: Pasin, Chloé, et al.
Publicado: (2019)

LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency
por: Weidenthaler, Heinz, et al.
Publicado: (2022)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization()
por: Dahlke, Christine, et al.
Publicado: (2017)

Asymptomatic Mpox Virus Infection in Subjects Presenting for MVA-BN Vaccine
por: Matusali, Giulia, et al.
Publicado: (2023)

Filo-Bobos /
por: Cortés Hernández, Jaime
Publicado: (1994)

Los filos
por: Martínez Gamba, Magaly, 1948-
Publicado: (1981)

Hall sensors batch-fabricated on all-CVD h-BN/graphene/h-BN heterostructures
por: Dankert, André, et al.
Publicado: (2017)

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo
por: Watson-Jones, Deborah, et al.
Publicado: (2022)

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment()
por: Custers, Jerome, et al.
Publicado: (2021)

En el filo /
por: Revueltas, José, 1914-1976
Publicado: (2000)

El último filo
por: Prada Oropeza, Renato, 1937-
Publicado: (1975)

Letra con filo
por: Rodríguez, Carlos Rafael
Publicado: (1987)

Viviendo al filo /
por: Mansour Manzur, Vivian

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
por: Zaeck, Luca M., et al.
Publicado: (2022)

LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios
por: Maclennan, Jane, et al.
Publicado: (2019)

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
por: Sadoff, Jerald, et al.
Publicado: (2022)

Al filo del agua
por: Yáñez, Agustín, 1904-1980
Publicado: (1993)

Al filo del deseo
por: Reyes Martínez, Alfoso
Publicado: (2009)

Al filo del agua
por: Yáñez, Agustín, 1904-1980
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_f7po24m6d336vsoaoldbi3bgq4